From emerging therapies to earlier intervention and psychosocial support, Dermatology Times looks back at key alopecia areata developments in 2026.

The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.

Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.

Alexandra Charrow, MD, discussed biologic selection, deroofing, and emerging procedural approaches to hidradenitis suppurativa at Maui Derm NP+PA Fall 2026.